Review



anti brg1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc anti brg1
    Anti Brg1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/bio_rxiv__64898__2026__03__27__714789-411-3-15?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    anti brg1 - by Bioz Stars, 2026-08
    86/100 stars

    Images



    Similar Products

    brg1 antibody / smarca4  (NSJ Bioreagents)
    99
    NSJ Bioreagents brg1 antibody / smarca4
    Brg1 Antibody / Smarca4, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/custom%40rq5493%4042497239?v=NSJ+Bioreagents
    Average 99 stars, based on 1 article reviews
    brg1 antibody / smarca4 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    brm brg1 atpase swi snf inhibitor brm014  (MedChemExpress)
    95
    MedChemExpress brm brg1 atpase swi snf inhibitor brm014
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Brm Brg1 Atpase Swi Snf Inhibitor Brm014, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/bio_rxiv__64898__2026__07__01__735834-260-11-16?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    brm brg1 atpase swi snf inhibitor brm014 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    brg1 antibody  (Servicebio Inc)
    86
    Servicebio Inc brg1 antibody
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Brg1 Antibody, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/pm42236527-75-17-19?v=Servicebio+Inc
    Average 86 stars, based on 1 article reviews
    brg1 antibody - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    brm014  (MedChemExpress)
    95
    MedChemExpress brm014
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Brm014, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/pm42097491-284-9-12?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    brm014 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    swi snf atpase inhibitor brm014  (MedChemExpress)
    95
    MedChemExpress swi snf atpase inhibitor brm014
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Swi Snf Atpase Inhibitor Brm014, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/pm42034057-495-16-20?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    swi snf atpase inhibitor brm014 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    smarca4  (Proteintech)
    93
    Proteintech smarca4
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Smarca4, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/pm41881959-314-5-6?v=Proteintech
    Average 93 stars, based on 1 article reviews
    smarca4 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    brg1  (Proteintech)
    93
    Proteintech brg1
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Brg1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/pm41921762-139-13-14?v=Proteintech
    Average 93 stars, based on 1 article reviews
    brg1 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    anti brg1  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc anti brg1
    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples <t>(BRM/BRG1</t> ATP Inhibitor-1 - <t>BRM014;</t> 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).
    Anti Brg1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brg1/bio_rxiv__64898__2026__03__27__714789-411-3-15?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    anti brg1 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples (BRM/BRG1 ATP Inhibitor-1 - BRM014; 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).

    Journal: bioRxiv

    Article Title: A Conserved Chromatin-Driven Checkpoint Defines Late Macrophage Maturation Independent of Tissue Specialization

    doi: 10.64898/2026.07.01.735834

    Figure Lengend Snippet: A) Genomic Locus Overlap Enrichment Analysis (LOLA) of differentially accessible regions (DARs) between day 13 and day 11, stratified according to the four clusters defined in A) (open promoter, n = 477 DARs; open distal, n = 368 DARs; closed promoter, n = 309 DARs; closed distal, n = 1,008 DARs). Enrichment was performed against the database of transcriptional regulators peaks from ReMap2022. Statistical significance was assessed using Fisher’s exact test implemented in LOLA (FDR-adjusted p < 0.05). The x-axis represents the odds ratio, and adjusted FDR values are indicated in the labels (ns, grey; FDR < 0.05, light blue; FDR < 0.005, blue; FDR < 0,0005 dark blue). The background universe corresponds to all accessible regions detected in the ATAC-Seq dataset. B) Functional enrichment analysis of the nearest associated genes to the defined DARs using ChEA gene sets. , Enrichment was assessed using a one-sided hypergeometric test with false discovery rate correction (Benjamini–Hochberg). The x-axis shows the number of enriched genes, and adjusted P values are indicated in the labels. The background gene universe corresponds to all genes associated with peak detected in the ATAC-seq dataset. C) Heatmap of differentially expressed genes (DEGs) induced by BAF inhibition, identified by comparing BAF inhibitor–treated samples (BRM/BRG1 ATP Inhibitor-1 - BRM014; 0.016, 0.08, and 0.4 µM; pink gradient from light to dark) to untreated controls. The inhibitor was applied at day 12 and RNA was collected at day 13 (DESeq2 with apeglm LFC shrinkage; adjusted p < 0.05; |fold change| > 1.5). Expression values are scaled by row (turquoise to yellow).

    Article Snippet: On day 12, cells were treated for 24 h with the BRM/BRG1 ATPase (SWI/SNF) inhibitor BRM014 (MedChemExpress, cat. no. HY-119374) at final concentrations of 400, 80, or 16 nM, with PBS-treated wells included as controls.

    Techniques: Functional Assay, Inhibition, Expressing